Literature DB >> 22986756

Percutaneous irreversible electroporation (IRE) of hepatic malignant tumours: contrast-enhanced ultrasound (CEUS) findings.

P Wiggermann1, F Zeman, C Niessen, A Agha, B Trabold, C Stroszczynski, E M Jung.   

Abstract

PURPOSE: The aim of this study is to describe the image findings of contrast-enhanced ultrasound (CEUS) after irreversible electroporation (IRE), and to assess its usefulness in relation to the evaluation of the ablation status using a dynamic recording of the microvascularisation. MATERIAL AND
METHOD: In this prospectively designed study, a percutaneous IRE was performed for the treatment of malignant hepatic lesions in a total of 15 patients following the interdisciplinary diagnosis. The lesions were documented using CEUS before, immediately after and 20 minutes after the ablation. The acquired CEUS image data was subsequently independently retrospectively evaluated by 2 experienced radiologists and assessed in relation to microvascularisation using a 5 point scale.
RESULTS: Using CEUS, a significant reduction in the microcirculation of the lesions, both centrally and marginally, could be detected following IRE (p < 0.001 and p < 0.001). The mean evaluation of the central microcirculation was reduced from 3.13 ± 1.38 to 0.47 ± 0.64 (p < 0.01). For the peripheral area of the lesion and the ablation margin, there was a reduction of 3.37 ± 1.13 to 1.57 ± 0.46 (p = 0.001). There was no significant reduction in the macrocirculation.
CONCLUSION: Within the framework of this study, it could be demonstrated that, in the course of IRE, a rapid significant reduction of the microcirculation in the ablation area occurred.

Entities:  

Mesh:

Year:  2012        PMID: 22986756     DOI: 10.3233/CH-2012-1615

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  9 in total

1.  Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties.

Authors:  Eliel Ben-David; Muneeb Ahmed; Mohammad Faroja; Marwan Moussa; Ayelet Wandel; Jacob Sosna; Liat Appelbaum; Isaac Nissenbaum; S Nahum Goldberg
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

2.  [Interventional sonography of the liver and kidneys].

Authors:  D-A Clevert; E M Jung
Journal:  Radiologe       Date:  2013-11       Impact factor: 0.635

Review 3.  Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment.

Authors:  Davide Roccarina; Matteo Garcovich; Maria Elena Ainora; Laura Riccardi; Maurizio Pompili; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  World J Hepatol       Date:  2015-07-18

4.  The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.

Authors:  W van den Bos; D M de Bruin; B G Muller; I M Varkarakis; A A Karagiannis; P J Zondervan; M P Laguna Pes; D P Veelo; C D Savci Heijink; M R W Engelbrecht; H Wijkstra; T M de Reijke; J J M C H de la Rosette
Journal:  BMJ Open       Date:  2014-10-29       Impact factor: 2.692

5.  Irreversible Electroporation for the Ablation of Renal Cell Carcinoma: A Prospective, Human, In Vivo Study Protocol (IDEAL Phase 2b).

Authors:  Mara Buijs; Krijn P van Lienden; Peter Gk Wagstaff; Matthijs Jv Scheltema; Daniel M de Bruin; Patricia J Zondervan; Otto M van Delden; Ton G van Leeuwen; Jean Jmch de la Rosette; M Pilar Laguna
Journal:  JMIR Res Protoc       Date:  2017-02-16

6.  Irreversible electroporation in patients with liver tumours: treated-area patterns with contrast-enhanced ultrasound.

Authors:  Linyu Zhou; Shanyu Yin; Weilu Chai; Qiyu Zhao; Guo Tian; Danxia Xu; Tian'an Jiang
Journal:  World J Surg Oncol       Date:  2020-11-23       Impact factor: 2.754

7.  Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma.

Authors:  Beata D Przybyla; Gal Shafirstein; Sagar J Vishal; Richard A Dennis; Robert J Griffin
Journal:  Int J Oncol       Date:  2013-11-21       Impact factor: 5.650

Review 8.  Evolving ablative therapies for hepatic malignancy.

Authors:  Smit Singla; Steven N Hochwald; Boris Kuvshinoff
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

9.  MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.

Authors:  Willemien van den Bos; D M de Bruin; A van Randen; M R W Engelbrecht; A W Postema; B G Muller; I M Varkarakis; A Skolarikos; C D Savci-Heijink; R R Jurhill; P J Zondervan; M P Laguna Pes; H Wijkstra; T M de Reijke; J J M C H de la Rosette
Journal:  Eur Radiol       Date:  2015-10-08       Impact factor: 5.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.